UroAlerts - Prostate Cancer Weekly

November 05, 2024

Videos

Peer-to-Peer Clinical Conversations

Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen

Zachary Klaassen

Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results.

Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James

Nicholas James

Nicholas James and Minal Padden-Modi discuss the STAMPEDE2 trial Arm P, which examines the use of upfront accelerated lutetium-PSMA-617 in metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer Trial - Beyond the Abstract

Long Noncoding RNA EPCART Regulates Translation Through PI3K/AKT/mTOR Pathway and PDCD4 in Prostate Cancer - Beyond the Abstract

Conference Coverage

SCS AUA 2024: Urothelial Carcinoma of the Prostate and Intravesical Therapy: A Cautionary Tale

SCS AUA 2024: Clinical Trial Updates for Treatment of Metastatic Prostate Cancer

SCS AUA 2024: Focal Therapy in Prostate Cancer

SCS AUA 2024: Active Surveillance for Low Volume Gleason Grade Group 2 Disease: Con

SCS AUA 2024: Active Surveillance for Intermediate Risk Prostate Cancer

Physician-Scientist Review Articles

ESMO 2024 Quick Take Insights: A Focus on ARANOTE

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract

The Use of Novel Instrumented Socks to Detect Changes in Daily Life Mobility During an Exercise Intervention in Prostate Cancer Survivors Treated with Androgen Deprivation Therapy.

Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer.

The association between patient characteristics, psychological distress, and coping in the diagnostic phase of prostate cancer – A cross-sectional multicenter study

Black men's experiences of support following treatment for prostate cancer in England: A qualitative study.

Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.

Pesticides and prostate cancer incidence and mortality: An environment-wide association study.

The Complex Challenge of Urosymphyseal Fistula and Pubic Osteomyelitis in Prostate Cancer Survivors.

County-level racial disparities in prostate cancer specific mortality from 2005 to 2020.

Evaluating the Importance of Practice-Level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology.

The TALAPRO-3 study design: a plain language summary.

In Major Win for Patients, CMS Adjusts Nuclear Medicine Reimbursement Policy, Expanding Access to Life-Saving Scans

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.

Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial.

Germline genetic testing for prostate cancer: Ordering trends in the era of expanded hereditary cancer screening recommendations.

Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer.

Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy.

Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing.

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.

PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases.

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617.

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.

FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.

Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.

Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.

A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing.

Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy.

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-W

Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study.

Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.

Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.

Identifying the best candidate for focal therapy: a comprehensive review.

The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer.

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.

What's in a Name? Why Words Matter in Advanced Prostate Cancer.

Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study.

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy - Beyond the Abstract

Testosterone Therapy in Men after Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer - Beyond the Abstract

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-Analysis with Bayesian Modeling of Treatment Histories - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC